ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders "
Episode Synopsis
CME credits: 1.00
Valid until: 24-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/tbd/37675/
Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.
Valid until: 24-09-2026
Claim your CME credit at https://reachmd.com/programs/cme/tbd/37675/
Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.
More episodes of the podcast ReachMD CME
The Fifth Pillar? Closing the Gap in HFrEF
14/11/2025
MOA: CDH6-Targeted Antibody-Drug Conjugates
14/11/2025
In God we trust